Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Targeted liposomal drug delivery systems for the treatment of B cell malignancies.

Mittal NK, Bhattacharjee H, Mandal B, Balabathula P, Thoma LA, Wood GC.

J Drug Target. 2014 Jun;22(5):372-86. doi: 10.3109/1061186X.2013.878942. Epub 2014 Jan 16. Review.

PMID:
24433007
2.

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.

Sapra P, Allen TM.

Clin Cancer Res. 2004 Apr 1;10(7):2530-7. Erratum in: Clin Cancer Res. 2004 Jul 15;10(14);4893.

5.

Targeting CD22 in B-cell malignancies: current status and clinical outlook.

Sullivan-Chang L, O'Donnell RT, Tuscano JM.

BioDrugs. 2013 Aug;27(4):293-304. doi: 10.1007/s40259-013-0016-7. Review.

PMID:
23696252
6.

In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

Lopes de Menezes DE, Pilarski LM, Allen TM.

Cancer Res. 1998 Aug 1;58(15):3320-30.

7.

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy N.

Clin Cancer Res. 2013 Jan 15;19(2):347-56. doi: 10.1158/1078-0432.CCR-12-2046. Epub 2012 Dec 3.

8.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
9.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
10.

Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.

Visani G, Isidori A.

Expert Rev Anticancer Ther. 2009 Mar;9(3):357-63. doi: 10.1586/14737140.9.3.357. Review.

PMID:
19275512
11.
12.

Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.

Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT.

Clin Cancer Res. 2010 May 15;16(10):2760-8. doi: 10.1158/1078-0432.CCR-09-3199. Epub 2010 May 11.

13.

In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC.

Blood. 2010 Jun 10;115(23):4778-86. doi: 10.1182/blood-2009-12-257386. Epub 2010 Feb 24. Erratum in: Blood. 2011 May 19;117(20):5551.

14.
15.

Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.

Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Biomaterials. 2013 Aug;34(26):6185-93. doi: 10.1016/j.biomaterials.2013.04.063. Epub 2013 May 28.

16.

Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells.

Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R, Jiang Y, He F.

Cancer Lett. 2008 Sep 28;269(1):26-36. doi: 10.1016/j.canlet.2008.04.024. Epub 2008 Jun 4.

PMID:
18534744
17.

Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.

Shahin M, Soudy R, El-Sikhry H, Seubert JM, Kaur K, Lavasanifar A.

Cancer Lett. 2013 Jul 1;334(2):284-92. doi: 10.1016/j.canlet.2012.10.007. Epub 2012 Oct 13.

PMID:
23073474
18.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
19.

Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.

Chen WC, Sigal DS, Saven A, Paulson JC.

Leuk Lymphoma. 2012 Feb;53(2):208-10. doi: 10.3109/10428194.2011.604755. Epub 2011 Aug 24. Review.

20.

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.

DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK.

Cancer Chemother Pharmacol. 2011 Apr;67(4):741-9. doi: 10.1007/s00280-010-1342-9. Epub 2010 Jun 3.

PMID:
20521053

Supplemental Content

Support Center